Drug Trial Radar · NCT01730404
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
Last checked: Nov 19, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Oct 2012
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of daily inhaled dosing.
Conditions
- COPD
Interventions
CHF6001 DPIDrug
RoflumilastDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events, adverse drug reactions, serious adverse.Time frame: After 28 days of treatment
- Vital signsTime frame: After 28 days of treatment
- 12-lead ECG parametersTime frame: After 28 days of treatment
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Celerion
Belfast, Ireland
Parexel, early phases
Harrow, United Kingdom
Medicines Evaluation Unit Ltd
Manchester, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.